Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Patients with metastatic renal cell cancer will be enrolled to receive RAD001 to determine
whether the use of RAD001 will result in an improvement in the time to tumor progression.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System